

RESEARCH
BOB Economics Research | Weekly Wrap

Early indicators point to sharp dip in growth

Sun Pharma | Target: Rs 445 | +32 % | REDUCE

USFDA classifies Halol site as OAI

SUMMARY
India Economics: Weekly Wrap

Global markets responded positively to US fiscal stimulus. Sharp dip in global services PMIs (US: 10ppt, Euro: 24ppt) and US consumer sentiment implies demand will decelerate in the coming days. India is in complete lockdown till 14 April. Government announced Rs 1.7tn fiscal stimulus and RBI did a 75bps reduction in repo rate along with Rs 3.74tn of liquidity infusion and 3-month moratorium on existing loans. More such measures will follow. 10Y yield hasn't fallen in-line as markets expect increase in government borrowings.

[Click here for the full report.](#)
Sun Pharma

The USFDA has classified Sun Pharma's (SUNP) key formulation site Halol under OAI (official action indicated). This site was inspected during 3-13 Dec 2019 and received eight observations (no data integrity issues but several lapses around quality control). The OAI is in line with our expectations and the risk of an import alert is low. SUNP will continue to engage with the FDA to regain cGMP compliance. We maintain our REDUCE rating on SUNP in view of slower-than-expected Ilumya scale up and likely earnings risk from Covid-19 (we estimate a 20% EPS CAGR for FY20-FY22).

[Click here for the full report.](#)
TOP PICKS
LARGE-CAP IDEAS

Company	Rating	Target
Bajaj Finance	Buy	5,200
Cipla	Buy	570
Eicher Motors	Buy	25,000
Petronet LNG	Buy	330
Reliance Industries	Buy	1,500

MID-CAP IDEAS

Company	Rating	Target
Alkem Labs	Buy	2,870
Greenply Industries	Buy	205
Laurus Labs	Buy	510
Transport Corp	Buy	355
Ashok Leyland	Sell	64

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.67	(17bps)	(66bps)	(172bps)
India 10Y yield (%)	6.14	(8bps)	(21bps)	(118bps)
USD/INR	74.92	0.3	(4.5)	(8.0)
Brent Crude (US\$/bbl)	24.93	(5.4)	(53.3)	(63.2)
Dow	21,637	(4.1)	(19.7)	(15.9)
Shanghai	2,772	0.3	(7.2)	(7.4)
Sensex	29,816	(0.4)	(25.3)	(22.6)
India FII (US\$ mn)	26 Mar	MTD	CYTD	FYTD
FII-D	(243.0)	(7,368.8)	(8,935.9)	(5,991.8)
FII-E	1.5	(7,542.1)	(5,755.1)	1,634.1

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



WEEKLY WRAP

30 March 2020

Early indicators point to sharp dip in growth

Global markets responded positively to US fiscal stimulus. Sharp dip in global services PMIs (US: 10ppt, Euro: 24ppt) and US consumer sentiment implies demand will decelerate in the coming days. India is in complete lockdown till 14 April. Government announced Rs 1.7tn fiscal stimulus and RBI did a 75bps reduction in repo rate along with Rs 3.74tn of liquidity infusion and 3-month moratorium on existing loans. More such measures will follow. 10Y yield hasn't fallen in-line as markets expect increase in government borrowings.

Sameer Narang | Aditi Gupta

chief.economist@bankofbaroda.com

Markets

- Bonds:** Global yields closed lower as global economic outlook remains jittery. US 10Y yield fell by 17bps (0.67%) on the back of increase in jobless claims and sharp dip in consumer sentiment. Oil prices fell by (-) 7.6% (US\$ 25/bbl) due to muted demand. India's 10Y yield fell by 12bps (6.14%) supported by RBI's rate cut of 75bps and liquidity infusion measures of Rs 3.74tn. System liquidity surplus rose to Rs 3.2tn as on 27 Mar 2020 vs Rs 2.2tn in the previous week.
- Currency:** DXY fell by (-) 4.3% from a 3-year high, registering its biggest weekly decline since CY09 as dollar liquidity improved. Most global currencies closed higher, led by GBP which rose by 7.1%. INR rose by 0.4% in the week after depreciating to a lifetime low as government and RBI unveiled measures to combat the economic fallout of Covid-19. FII outflows continued (US\$ 1.4bn in the week).
- Equity:** Barring Sensex, global indices ended the week higher on the back of monetary and fiscal measures to counter the impact of COVID-19. US cleared US\$ 2tn fiscal stimulus. Nikkei (17.1%) surged the most followed by Dow (12.8%). Sensex pared losses to end the week lower by only (-) 0.3% on the back of government stimulus and RBI's monetary easing measures.
- Upcoming key events:** In the current week, markets will continue to monitor daily increase in COVID-19 confirmed cases which have increased by 373k vs 165k last week. Manufacturing and services PMIs along with US ISM index, factory orders and unemployment rate will be in focus. On the domestic front, H1FY21 borrowing calendar, PMIs, core industry data and fiscal deficit data is awaited.



REDUCE

TP: Rs 445 | ▲ 32%

SUN PHARMA

Pharmaceuticals

30 March 2020

USFDA classifies Halol site as OAI

What's new: The USFDA has classified Sun Pharma's (SUNP) key formulation site Halol under OAI (official action indicated). This site was inspected during 3-13 Dec 2019 and received eight observations (no data integrity issues but several lapses around quality control). The OAI is in line with our expectations and the risk of an import alert is low. SUNP will continue to engage with the FDA to regain cGMP compliance.

Implications: Halol is a key facility for SUNP's US business with a large manufacturing capacity for complex orals, injectables and dermatology drugs, among others. Current business, which in our view is US\$ 150mn-200mn (i.e. 3-4% of overall company FY20 sales), from this site will continue.

Future approvals (the site has 19 pending ANDAs as per the company) will be delayed due to the OAI, but this is likely to have limited earnings impact since the company has partly derisked key filings from this site to the Baska and Pharmeducence plants since 2015 (both have complex injectable manufacturing capabilities). But we highlight that the Baska unit has just a fourth of the capacity at Halol and hence may face supply constraints in the medium term.

Retain REDUCE: We maintain our REDUCE rating on SUNP in view of slower-than-expected Ilumya scale up and likely earnings risk from Covid-19 (we estimate a 20% EPS CAGR for FY20-FY22). Other concerns constraining valuations include potential penalty by DOJ in the price fixing case, the SEBI-ordered forensic audit of 2016-18 financials, and the Rs 40.6bn contingent tax liability not provided for. The stock is trading at reasonable valuations of 15x FY21E EPS.

Vivek Kumar

research@bobcaps.in

Ticker/Price	SUNP IN/Rs 338
Market cap	US\$ 10.8bn
Shares o/s	2,399mn
3M ADV	US\$ 36.6mn
52wk high/low	Rs 484/Rs 315
Promoter/FPI/DII	54%/17%/16%


Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY20E	FY21E	FY22E
Total revenue (Rs mn)	325,880	359,740	400,315
EBITDA (Rs mn)	73,200	82,929	91,855
Adj. net profit (Rs mn)	47,500	55,534	62,602
Adj. EPS (Rs)	19.8	23.1	26.1
Adj. EPS growth (%)	30.2	16.9	12.7
Adj. ROAE (%)	10.1	10.8	11.1
Adj. P/E (x)	17.1	14.6	13.0
EV/EBITDA (x)	10.2	8.9	7.6

Source: Company, BOBCAPS Research

STOCK PERFORMANCE



Source: NSE

[Click here for our last detailed report](#)


Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 29 February 2020, out of 85 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 17 are rated ADD, 9 are rated REDUCE and 9 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.